🟢 BioLineRx is trading 6.5% up today on continued momentum from recent licensing and financing deals

BioLineRx is trading 6.5% up at $3.02 on continued momentum from recent licensing and financing deals.

• Sentiment remains supported by a recent licensing agreement with Ayrmid Pharma for APHEXDA (motixafortide) and approximately $19 million in new financing.
• The gain comes despite a broadly weaker biotech sector today, suggesting the move is driven by stock-specific buying interest rather than industry trends.
• There are no fresh company-specific headlines for July 21, 2026, to explain the move beyond the carryover from recent catalysts.